InsiderSignal.AI

InsiderSignal.ai

RAPP - Rapport Therapeutics, Inc.

Insider Purchase by Paul Steven M (Dir)

6 Months
After Trade
Before Trade

Loading data...

Trade Summary

5 months ago, Paul Steven M, serving as Dir at Rapport Therapeutics, Inc. (RAPP), purchased 41,666 shares at $24.65 per share, for a total transaction value of $1,027,111.00. Following this transaction, Paul Steven M now holds 41,666 shares of RAPP.

The trade was executed on Friday, September 12, 2025 and publicly disclosed via SEC Form 4 filing on Monday, September 15, 2025, 3 days after the trade was made.

Rapport Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider buying activity in this sector can provide valuable signals about industry trends and company-specific developments.

Paul Steven M

Dir

Dr. Steven M. Paul, M.D. is the Founder and Independent Chairman of Rapport Therapeutics, Inc. (RAPP), a clinical-stage biopharmaceutical company focused on developing small molecule medicines for central nervous system (CNS) disorders, including its lead candidate RAP-219 for focal epilepsy and other conditions.[[1]](https://stockanalysis.com/stocks/rapp/company/)[[2]](https://www.rapportrx.com/about/board-of-directors/)[[3]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rapp/rapport-therapeutics/management) As a director, he has recently engaged in insider trading activity, including acquiring 41,666 shares valued at approximately $1,027,111 and receiving 21,850 stock options on June 17, 2025.[[4]](https://www.stocktitan.net/sec-filings/RAPP/form-4-rapport-therapeutics-inc-insider-trading-activity-b4557d2d2e1f.html)[[5]](https://www.gurufocus.com/news/3108642/rapport-therapeutics-rapp-director-acquires-significant-shares)[[6]](https://www.secform4.com/insider-trading/1237564.htm) Dr. Paul brings over 40 years of R&D leadership in neuroscience, having co-founded companies such as Karuna Therapeutics, Sage Therapeutics, and Voyager Therapeutics, and currently serving as Chief Scientific Officer and President of R&D at Karuna while on the board of Sage.[[2]](https://www.rapportrx.com/about/board-of-directors/) His career includes 18 years at the National Institutes of Health as Scientific Director of the National Institute of Mental Health, followed by 17 years at Eli Lilly & Co., rising to Executive Vice President for Science and Technology and President of Lilly Research Laboratories.[[2]](https://www.rapportrx.com/about/board-of-directors/) He holds a bachelor’s in Biology and Psychology, M.S., and M.D. from Tulane University School of Medicine, and is a Professor of Psychiatry and Neurology at Washington University School of Medicine.[[2]](https://www.rapportrx.com/about/board-of-directors/)

View full insider profile →

Trade Price

$24.65

Quantity

41,666

Total Value

$1,027,111.00

Shares Owned

41,666

Trade Date

Friday, September 12, 2025

163 days ago

SEC Filing Date

Monday, September 15, 2025

Filed 3 days after trade

HEALTHCAREBIOTECHNOLOGY

About Rapport Therapeutics, Inc.

Company Overview

No company information available
View news mentioning RAPP

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/348324

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime